Abstract
The two monoclonal antibodies (mAb), L6 (anti-carcinoma), and 1F5 [anti-(B-cell-lymphoma)], were chemically linked to the enzyme penicillin-V amidase (PVA), which hydrolyzes phenoxyacetamides, to explore the potential of using mAb-enzyme conjugates for the localization of chemotherapeutic drugs at tumor cells. The phenoxyacetamide derivatives of doxorubicin and melphalan were prepared, yielding the less toxic amides, doxorubicin-N-p-hydroxyphenoxyacetamide (DPO) and melphalan-N-p-hydroxyphenoxyacetamide (MelPO). These were hydrolyzed by PVA to doxorubicin and melphalan respectively. In vitro studies with the L6-positive lung carcinoma cell line, H2981, and the 1F5-positive B-cell lymphoma line, Daudi, showed that DPO was 80-fold less toxic to H2981 cells and 20-fold less toxic to Daudi cells than doxorubicin, and its toxicity was substantially increased when the H2981 cells were pretreated with L6-PVA or the Daudi cells were pretreated with 1F5-PVA. The cytotoxic effect was antigen-specific, since only the binding mAb-enzyme conjugate increased the cytotoxicity of the prodrug. MelPO was more than 1000-fold less toxic than melphalan to H2981 cells and more than 100-fold less toxic than melphalan to Daudi cells. Pretreatment with...Continue Reading
References
Feb 1, 1979·FEBS Letters·Y Levin, B A Sela
Apr 19, 1989·Journal of the National Cancer Institute·R K Jain
Mar 1, 1988·Cancer·T TakahashiY Hashimoto
Dec 1, 1988·British Journal of Cancer·K D BagshaweR F Sherwood
Nov 20, 1987·Science·E S VitettaJ W Uhr
Jul 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·P D SenterK E Hellström
Feb 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·H M Yang, R A Reisfeld
Dec 5, 1986·Cell·I PastanD J FitzGerald
Mar 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·E A ClarkJ A Ledbetter
Jan 1, 1984·Australian Journal of Biological Sciences·W L Baker
Jan 1, 1982·Springer Seminars in Immunopathology·K E HellströmJ P Brown
Nov 4, 1983·Science·D A ValleraR J Youle
Jan 1, 1983·Pharmacology & Therapeutics·D C Edwards
Sep 1, 1982·Immunology Letters·G PeltreB David
Nov 1, 1980·Journal of Medicinal Chemistry·R BaurainA Trouet
Citations
Jun 1, 1993·Cancer Metastasis Reviews·R J KnoxM P Boland
Oct 8, 1999·Pharmacology & Therapeutics·G M Dubowchik, M A Walker
Jul 7, 1997·Advanced Drug Delivery Reviews·C J Springer, I Niculescu-Duvaz
Jul 7, 1997·Advanced Drug Delivery Reviews·D J KerrI A McNeish
Oct 12, 1996·Annals of the New York Academy of Sciences·B AvalleA Friboulet
Jan 1, 1992·Cancer Immunology, Immunotherapy : CII·H J HaismaH M Pinedo
Sep 1, 1995·Stem Cells·T A Connors, R J Knox
Sep 1, 1996·International Journal of Oncology·B RettaE Enoamooquaye
Dec 30, 1999·Journal of Drug Targeting·J Y LuP S Low
Jan 1, 1992·Acta Oncologica·D C Blakey
Jun 15, 2007·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Sachin MittalGordon L Amidon
Jan 1, 1991·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·K E Hellström, P D Senter
May 26, 1995·Biochemical Pharmacology·R J KnoxR F Sherwood
Dec 23, 2014·Medicinal Research Reviews·Herve Aloysius, Longqin Hu
Jul 10, 2014·The AAPS Journal·Irene GiangGregory M K Poon
Oct 16, 2016·Expert Opinion on Biological Therapy·Surinder K Sharma, Kenneth D Bagshawe
Mar 1, 1992·Bioconjugate Chemistry·H P SvenssonP D Senter
Jul 1, 1995·Bioconjugate Chemistry·D L MeyerJ J Starling
Jan 1, 1992·Bioconjugate Chemistry·D L MeyerC N Ahlem
Dec 2, 1998·International Journal of Cancer. Journal International Du Cancer·K N SyrigosA A Epenetos
Jul 22, 2014·Behavioral Sciences & the Law·Kathleen M Heide, Brian G Sellers
Mar 6, 2004·Pharmacological Reviews·Martijn RooseboomNico P E Vermeulen
Jan 1, 1994·Cell Biophysics·C J SpringerK D Bagshawe